New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
10:23 EDTSWHC, RMTI, MTOR, APOL, NWBO, SBGI, UNXL, ACHN, VRTX, OHRPOptions with decreasing implied volatility
Options with decreasing implied volatility: OHRP VRTX ACHN UNXL SBGI NWBO APOL MTOR RMTI SWHC
News For OHRP;VRTX;ACHN;UNXL;SBGI;NWBO;APOL;MTOR;RMTI;SWHC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
07:52 EDTACHNJ&J purchase of Alios an incremental negative for Achillion, says UBS
UBS views Johnson & Johnson's (JNJ) purchase of Alios as an incremental negative for Achillion (ACHN), as it implies there is now one less potential buyer of the company. However, the firm still thinks ACH-3422 will have considerable strategic value after data is reported and that other HCV players such as AbbVie (ABBV) and Bristol-Myers (BMY) are likely to be interested. UBS maintains its Buy rating and $15 price target on Achillion.
07:50 EDTVRTXVertex reinstated with a Neutral at BofA/Merrill
Subscribe for More Information
September 30, 2014
12:40 EDTACHNOn The Fly: Midday Wrap
Subscribe for More Information
12:03 EDTACHNAchillion sinks after Johnson & Johnson buys competitor
The shares of Achillion (ACHN), which has developed a treatment for hepatitis C based on a nucleotide and has been viewed as a potential takeover target by analysts previously, are falling after Johnson & Johnson (JNJ) announced this morning that it had agreed to acquire privately held Alios Biopharma. Alios has developed a number of nucleotide-based hepatitis C treatments, as well as an orally administered antiviral therapy currently in Phase 2 studies for the treatment of infants with respiratory syncytial virus. WHAT'S NEW: Johnson & Johnson said that it had agreed to buy Alios for $1.75B. Alios has developed a number of nucleotides that could be used to treat hepatitis C virus, or HCV. Gilead's (GILD) popular HCV treatment Sovaldi is also a nucleotide and Achillion is developing its own HCV nucleotide treatment. According to The Street's Adam Feuerstein, Achillion's nucleotide is similar in structure to that of Alios. Johnson & Johnson had previously been rumored to be interested in buying Achillion, Feuerstein noted. WHAT'S NOTABLE: Johnson & Johnson said it was "excited" that its acquisition of Alios would enable it to "explore treatment options for a number of viral infections, including RSV, the last of the major pediatric diseases with no available preventive therapy." Novavax (NVAX) is also developing an RSV vaccine and Johnson & Johnson could have considered acquiring it before buying Alios, Feuerstein contended. PRICE ACTION: Near noon, Achillion fell 6% to $10.11, Gilead was down 0.6% to $106.84, Novavax dropped 1% to $4.27, and Johnson & Johnson rose 0.4% to just under $107 per share.
10:30 EDTACHNJ&J could have considered Novavax, Achillion instead of Alios, TheStreet says
Subscribe for More Information
September 29, 2014
13:33 EDTSBGISinclair Broadcast enters into long-term affiliation agreements with ABC
Sinclair Broadcast (SBGI) announced that it has entered into long-term agreements with Disney's (DIS) American Broadcasting Company for the renewal of the ABC affiliations in 13 Sinclair markets that come up for renewal during 2014 and 2015. Three of the new agreements will expire on August 31, 2019 and the other 11 will expire on August 31, 2020. The markets being renewed are listed below and include six of Sinclair's ten biggest ABC markets, including five of the top six ABC markets. The company's remaining ABC affiliation agreements do not expire for several years. The company said, "We are pleased to have reached this agreement with ABC to renew these affiliation agreements for 5-year terms including a number of agreements that were not set to expire until 2015."
11:48 EDTSBGISinclair Broadcast syndication agreements a positive, says Wells Fargo
Subscribe for More Information
10:01 EDTSBGISinclair Broadcast unit enters syndication agreements for ASN initiative
Subscribe for More Information
09:09 EDTVRTXVertex was boosted by several catalysts, says RBC Capital
Subscribe for More Information
08:33 EDTMTORMeritor sells Mascot Brand to investor group
Subscribe for More Information
September 26, 2014
18:50 EDTACHNRA Capital Management reduces passive stake in Achillion to 11.3% from 18.1%
10:18 EDTACHNOptions with decreasing implied volatility
Subscribe for More Information
September 25, 2014
15:38 EDTACHNAchillion CCO says NUC data won't be abstract at AASLD, Bloomberg reports
Subscribe for More Information
September 24, 2014
11:22 EDTVRTXOptions with increasing implied volatility
Subscribe for More Information
September 23, 2014
15:00 EDTACHNAchillion volatility elevated into expected release of viral data
Subscribe for More Information
11:19 EDTVRTX Options with increasing implied volatility
Options with increasing implied volatility: HLF VRTX TRP CLX ETP VALE
07:55 EDTVRTXVertex should be bought into recent strength, says Wells Fargo
Subscribe for More Information
September 22, 2014
11:26 EDTVRTXOptions with increasing implied volatility
Options with increasing implied volatility: SHLD VRTX TRP AGNC
September 18, 2014
07:24 EDTVRTXVertex management to meet with Deutsche Bank
Subscribe for More Information
07:17 EDTAPOLBMO Capital to hold a conference
14th Annual Back to School Education Conference to be held in New York on September 18 with webcasted company presentations to begin at 8 am; not all company presentations may be webcasted. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use